Medtronic (MDT)
(Delayed Data from NYSE)
$79.25 USD
-1.13 (-1.41%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $79.24 -0.01 (-0.01%) 7:04 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.25 USD
-1.13 (-1.41%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $79.24 -0.01 (-0.01%) 7:04 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medtronic (MDT) Laps the Stock Market: Here's Why
by Zacks Equity Research
Medtronic (MDT) reachead $80.57 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
The Zacks Analyst Blog Highlights Mastercard, Netflix, Coca-Cola, Berkshire Hathaway and Medtronic
by Zacks Equity Research
Mastercard, Netflix, Coca-Cola, Berkshire Hathaway and Medtronic are included in this Analyst Blog.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $79.35, signifying a -1.1% move from its prior day's close.
Q1 Earnings Scorecard and Analyst Reports for Mastercard, Netflix & Coca-Cola
by Sheraz Mian
Today's Research Daily features a real-time update on the Q1 earnings season and new research reports Mastercard (MA), Netflix (NFLX) and Coke (KO) and others.
Medtronic PLC (MDT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Medtronic (MDT) reachead $82.33 at the closing of the latest trading day, reflecting a -1.75% change compared to its last close.
Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $83.92, denoting a -1.27% change from the preceding trading day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval
by Zacks Equity Research
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
National Vision (EYE) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Expands in Canada With First Eterna SCS Use
by Zacks Equity Research
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
Medtronic (MDT) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
Medtronic's (MDT) MiniMed 780G System Study Data Favorable
by Zacks Equity Research
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic
by Zacks Equity Research
Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
MDT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDT vs. LMAT: Which Stock Is the Better Value Option?
Company News for Feb 21, 2024
by Zacks Equity Research
Companies in The News Are: WMT, MDT, NFLX, MPC
Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.
Medtronic (MDT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended January 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 3.17% and 1.73%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -4.88% and 9.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?